Atrium Therapeutics, Inc. Common Stock (RNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $162.00M
Last updated: Nov 17, 2026 at 11:06 AM ET
Atrium Therapeutics, Inc. Common Stock (RNA) Stock Forecast
Analysts expect Atrium Therapeutics, Inc. Common Stock (RNA) to earn -$3.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $35.02M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 95.4%.
- Fiscal year ending Dec 31, 2026
- -$3.87
- EPS consensus, revenue $35.02M
- Fiscal year ending Dec 31, 2027
- -$5.96
- EPS consensus, revenue $1.60M
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.87 | -$4.12 to -$3.61 | 2 | $35.02M | $22.64M to $39.60M | 5 |
| Dec 31, 2027 | -$5.96 | -$6.39 to -$5.53 | 2 | $1.60M | N/A | 5 |
Quarterly Estimates
The EPS consensus falls from -$1.26 for the quarter ending Dec 31, 2026 to -$1.43 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.26 | -$1.72 to -$0.39 | 6 | $404000 | N/A | 6 |
| Mar 31, 2027 | -$1.43 | -$1.57 to -$1.28 | 2 | N/A | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.59.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.87 | -$3.61 | -$4.55 | -$4.55 | -$3.59 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.96 | -$6.39 | -$8.06 | -$8.06 | -$5.85 | N/A |
| Quarter ending Mar 31, 2027 | -$1.43 | -$1.57 | -$1.98 | -$1.98 | -$1.44 | N/A |
Frequently Asked Questions About RNA
What is the RNA stock forecast?
Consensus analyst estimates put Atrium Therapeutics, Inc. Common Stock's EPS at -$3.87 for the fiscal year ending Dec 31, 2026, on revenue of $35.02M. The consensus rating from 5 analysts is Buy.
How do analysts rate RNA stock?
Of 5 analysts covering Atrium Therapeutics, Inc. Common Stock, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RNA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.87, with estimates from -$4.12 to -$3.61 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.96, with estimates from -$6.39 to -$5.53 from 2 analysts.
What revenue do analysts expect from Atrium Therapeutics, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $35.02M, with estimates from $22.64M to $39.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.60M.
How many analysts cover RNA?
5 analysts rate Atrium Therapeutics, Inc. Common Stock stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RNA pages: Overview, Earnings, Forecast, Financials, Competitors